KIORA PHARMACEUTICALS, INC. Payments of Financing Costs
KIORA PHARMACEUTICALS, INC. (KPRX) reported Payments of Financing Costs of $0 for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-25.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfFinancingCosts · last filed 2021-03-25
- KIORA PHARMACEUTICALS, INC. payments of financing costs for the quarter ending 2020-12-31 was $0.00.
- KIORA PHARMACEUTICALS, INC. payments of financing costs for the quarter ending 2020-09-30 was $0.00, a 100.00% decline year-over-year.
- KIORA PHARMACEUTICALS, INC. payments of financing costs for the quarter ending 2020-06-30 was $0.00, a 100.00% decline year-over-year.
- KIORA PHARMACEUTICALS, INC. payments of financing costs for the quarter ending 2020-03-31 was $0.00, a 100.00% decline year-over-year.
- KIORA PHARMACEUTICALS, INC. payments of financing costs for fiscal 2020 was $0.00, a 100.00% decline from fiscal 2019.
- KIORA PHARMACEUTICALS, INC. payments of financing costs for fiscal 2019 was $4.71K, a 51.80% decline from fiscal 2018.
- KIORA PHARMACEUTICALS, INC. payments of financing costs for fiscal 2018 was $9.78K, a 22.64% decline from fiscal 2017.
- KIORA PHARMACEUTICALS, INC. payments of financing costs for fiscal 2017 was $12.64K, a 341.67% increase from fiscal 2016.
| Period end | Payments of Financing Costs 3 month | Payments of Financing Costs 6 month | Payments of Financing Costs 9 month | Payments of Financing Costs 12 month |
|---|---|---|---|---|
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $0.00 derived: sum of 2 quarters · filed 2021-03-25 | $0.00 derived: sum of 3 quarters · filed 2021-03-25 | $0.00 10-K · filed 2021-03-25 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $0.00 derived: sum of 2 quarters · filed 2020-11-09 | $0.00 10-Q · filed 2020-11-09 | $0.00 derived: sum of 4 quarters · filed 2021-03-25 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $0.00 10-Q · filed 2020-08-06 | $0.00 derived: sum of 3 quarters · filed 2021-03-25 | $1.57K derived: sum of 4 quarters · filed 2021-03-25 |
| 2020-03-31 | $0.00 10-Q · filed 2020-05-06 | $0.00 derived: sum of 2 quarters · filed 2021-03-25 | $1.57K derived: sum of 3 quarters · filed 2021-03-25 | $3.14K derived: sum of 4 quarters · filed 2021-03-25 |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $1.57K derived: sum of 2 quarters · filed 2021-03-25 | $3.14K derived: sum of 3 quarters · filed 2021-03-25 | $4.71K 10-K · filed 2021-03-25 |
| 2019-09-30 | $1.57K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $3.14K derived: sum of 2 quarters · filed 2020-11-09 | $4.71K 10-Q · filed 2020-11-09 | $6.60K derived: sum of 4 quarters · filed 2020-11-09 |
| 2019-06-30 | $1.57K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $3.14K 10-Q · filed 2020-08-06 | $5.03K derived: sum of 3 quarters · filed 2020-08-06 | $6.60K derived: sum of 4 quarters · filed 2020-08-06 |
| 2019-03-31 | $1.57K 10-Q · filed 2020-05-06 | $3.46K derived: sum of 2 quarters · filed 2020-05-06 | $5.03K derived: sum of 3 quarters · filed 2020-05-06 | $8.19K derived: sum of 4 quarters · filed 2020-05-06 |
| 2018-12-31 | $1.89K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-04 | $3.46K derived: sum of 2 quarters · filed 2020-03-04 | $6.62K derived: sum of 3 quarters · filed 2020-03-04 | $9.78K 10-K · filed 2020-03-04 |
| 2018-09-30 | $1.57K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $4.73K derived: sum of 2 quarters · filed 2019-11-07 | $7.89K 10-Q · filed 2019-11-07 | $11.05K derived: sum of 4 quarters · filed 2019-11-07 |
| 2018-06-30 | $3.16K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $6.32K 10-Q · filed 2019-08-08 | $9.48K derived: sum of 3 quarters · filed 2019-08-08 | $12.64K derived: sum of 4 quarters · filed 2019-08-08 |
| 2018-03-31 | $3.16K 10-Q · filed 2019-05-08 | $6.32K derived: sum of 2 quarters · filed 2019-05-08 | $9.48K derived: sum of 3 quarters · filed 2019-05-08 | $12.64K derived: sum of 4 quarters · filed 2019-05-08 |
| 2017-12-31 | $3.16K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $6.32K derived: sum of 2 quarters · filed 2019-03-01 | $9.48K derived: sum of 3 quarters · filed 2019-03-01 | $12.64K 10-K · filed 2019-03-01 |
| 2017-09-30 | $3.16K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | $6.32K derived: sum of 2 quarters · filed 2018-11-13 | $9.48K 10-Q · filed 2018-11-13 | $12.35K derived: sum of 4 quarters · filed 2018-11-13 |
| 2017-06-30 | $3.16K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-03 | $6.32K 10-Q · filed 2018-08-03 | $9.19K derived: sum of 3 quarters · filed 2018-08-03 | $9.19K derived: sum of 4 quarters · filed 2018-08-03 |
| 2017-03-31 | $3.16K 10-Q · filed 2018-05-11 | $6.03K derived: sum of 2 quarters · filed 2018-05-11 | $6.03K derived: sum of 3 quarters · filed 2018-05-11 | $6.03K derived: sum of 4 quarters · filed 2018-05-11 |
| 2016-12-31 | $2.86K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-02 | $2.86K derived: sum of 2 quarters · filed 2018-03-02 | $2.86K derived: sum of 3 quarters · filed 2018-03-02 | $2.86K 10-K · filed 2018-03-02 |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-14 | $0.00 derived: sum of 2 quarters · filed 2017-11-14 | $0.00 10-Q · filed 2017-11-14 | |
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-04 | $0.00 10-Q · filed 2017-08-04 | ||
| 2016-03-31 | $0.00 10-Q · filed 2017-05-05 | |||
| 2015-12-31 | $0.00 10-K · filed 2017-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |